Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022
01 mars 2022 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility
10 janv. 2022 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments
07 déc. 2021 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy -- -- Signed $36 Million in...
Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer
07 oct. 2021 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments
08 sept. 2021 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- -- Signed $23 Million in New Business Orders and Ended the Quarter...
Avid Bioservices to Participate at Upcoming Investor Conferences
02 sept. 2021 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
01 juil. 2021 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
29 juin 2021 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 -- -- Signed...
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
25 mai 2021 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...
Avid Bioservices Announces Closing of Public Offering of Common Stock
14 déc. 2020 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to...